| NCT05711940 | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | RECRUITING | PHASE3 | 2023-02-14 | 2026-12 | 2026-02 |
| NCT05733546 | A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-01-30 | 2025-09 | 2025-09 |
| NCT05624268 | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-01-19 | 2026-04 | 2025-05-28 |
| NCT05481736 | Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | COMPLETED | PHASE2 | 2022-10-12 | 2024-11-18 | 2024-11-18 |
| NCT05312151 | The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | COMPLETED | PHASE2 | 2022-06-10 | 2024-02-12 | 2024-02-12 |
| NCT04739865 | The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression | COMPLETED | PHASE2 | 2020-08-10 | 2021-10-14 | 2021-10-14 |
| NCT03775200 | The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | COMPLETED | PHASE2 | 2019-03-01 | 2021-09-27 | 2021-07-30 |